We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · October 31, 2021

Molecular Correlates of Response to Eribulin and Pembrolizumab in HR+ Metastatic Breast Cancer

Nature Communications


Additional Info

Nature Communications
Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer
Nat Commun 2021 Sep 21;[EPub Ahead of Print], TE Keenan, JL Guerriero, R Barroso-Sousa, T Li, T O'Meara, A Giobbie-Hurder, N Tayob, J Hu, M Severgnini, J Agudo, I Vaz-Luis, L Anderson, V Attaya, J Park, J Conway, MX He, B Reardon, E Shannon, G Wulf, LM Spring, R Jeselsohn, I Krop, NU Lin, A Partridge, EP Winer, EA Mittendorf, D Liu, EM Van Allen, SM Tolaney

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading